Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao MS.

Clin Cancer Res. 2011 Jan 1;17(1):134-41. doi: 10.1158/1078-0432.CCR-10-2224. Epub 2010 Nov 16.

2.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

3.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

4.

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.

Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.

Cell Death Dis. 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217.

5.

Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.

Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS.

Int J Cancer. 2017 Feb 1;140(3):662-673. doi: 10.1002/ijc.30472. Epub 2016 Nov 7.

PMID:
27750381
6.

Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.

Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, Choi YL, Park WY, Lee HM, Seol HJ, Shim YM, Joo KM, Nam DH.

Clin Cancer Res. 2015 Mar 1;21(5):1172-82. doi: 10.1158/1078-0432.CCR-14-1589. Epub 2014 Dec 30.

7.

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.

Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, Su X, Zheng L, Zhu G, Zhan P, Ji Q, Wu YL.

J Transl Med. 2013 Jul 10;11:168. doi: 10.1186/1479-5876-11-168.

8.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

9.

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP.

J Thorac Oncol. 2008 Apr;3(4):331-9. doi: 10.1097/JTO.0b013e318168d9d4.

10.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.

PMID:
20100958
11.

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A.

Br J Cancer. 2008 Sep 16;99(6):923-9. doi: 10.1038/sj.bjc.6604629.

12.

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I.

J Thorac Oncol. 2006 Mar;1(3):231-9.

13.

Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.

Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY.

J Thorac Oncol. 2010 Nov;5(11):1734-40. doi: 10.1097/JTO.0b013e3181f0beca. Erratum in: J Thorac Oncol. 2011 Jun;6(6):1147.

14.

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V, Voutsina A.

Lung Cancer. 2010 Jul;69(1):110-5. doi: 10.1016/j.lungcan.2009.09.010. Epub 2009 Oct 24.

PMID:
19854533
15.

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].

Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, Sun BC, Zhan ZL.

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):667-70. Chinese.

PMID:
21122380
16.

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.

Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE; Cancer, Leukemia Group B, Chicago, IL.

J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657.

17.

Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan.

Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF.

J Thorac Oncol. 2010 Aug;5(8):1175-84. doi: 10.1097/JTO.0b013e3181e2f4d6.

18.

The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China.

Li M, Zhang Q, Liu L, Liu Z, Zhou L, Wang Z, Yue S, Xiong H, Feng L, Lu S.

Neoplasma. 2011;58(1):74-81.

PMID:
21067269
19.

Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer.

John T, Yanagawa N, Kohler D, Craddock KJ, Bandarchi-Chamkhaleh B, Pintilie M, Sykes J, To C, Li M, Panchal D, Chen W, Shepherd FA, Tsao MS.

J Thorac Oncol. 2012 Jul;7(7):1101-8. doi: 10.1097/JTO.0b013e3182519d4d.

20.

[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].

Han C, Zou H, Ma J, Zhou Y, Zhao J.

Zhongguo Fei Ai Za Zhi. 2010 Sep;13(9):882-91. doi: 10.3779/j.issn.1009-3419.2010.09.09. Review. Chinese.

Supplemental Content

Support Center